2:24 PM
 | 
Aug 16, 2018
 |  BC Extra  |  Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to treat chronic pain caused by osteoarthritis of the knee or hip. Fasinumab is a mAb against nerve growth factor (NGF).

Regeneron gained $9.91 to $371.78 on Thursday, for a gain of over $1 billion in market cap.

The substudy included 646 patients who received placebo or 1 mg subcutaneous fasinumab every eight weeks or every four weeks. The substudy is part of a larger trial that includes 52 weeks of active treatment in about 3,500 patients to...

Read the full 538 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >